CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy

Key Points

• CTLA-4 plays a vital role in regulating immune response, potentially impacting prostate cancer outcomes.
• Recent findings indicate enhanced therapeutic effects when targeting CTLA-4 in various prostate cancer models.
• Observational analysis of clinical trials shows improved patient responses to CTLA-4 blockade in prostate cancer therapy.
• These results highlight the potential of CTLA-4 as a novel therapeutic target in prostate cancer treatment.